Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.53 |
| ▸ | JAK3 | P52333 | 3/20 | 0.53 |
| ▸ | JAK1 | P23458 | 3/20 | 0.53 |
| ▸ | FLT3 | P36888 | 6/20 | 0.52 |
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.52 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.52 |
| ▸ | CDK7 | P50613 | 2/20 | 0.52 |
| ▸ | CCNH | P51946 | 2/20 | 0.52 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14100329 | 0.92 | CDK2 (0.52) | JAK2JAK3JAK1FLT3CDK2 | |
| SCHEMBL14100502 | 0.91 | CDK2 (0.51) | JAK2JAK3FLT3CDK2CCNE1 | |
| SCHEMBL14100355 | 0.91 | CDK2 (0.51) | JAK2JAK3JAK1FLT3CDK2 | |
| SCHEMBL14100325 | 0.90 | CDK2 (0.50) | JAK2JAK3JAK1FLT3CDK2 | |
| SCHEMBL14100359 | 0.90 | PTK2 (0.58) | JAK2JAK3JAK1FLT3CDK2 | |
| SCHEMBL14619443 | 0.90 | CDK2 (0.50) | JAK2JAK3JAK1FLT3CDK2 | |
| SCHEMBL14100354 | 0.90 | CDK2 (0.50) | JAK2JAK3FLT3CDK2CCNE1 | |
| SCHEMBL14100320 | 0.90 | JAK2 (0.51) | JAK2JAK3FLT3CDK2CCNE1 | |
| SCHEMBL14100315 | 0.90 | CDK2 (0.49) | JAK2JAK3JAK1FLT3CDK2 | |
| SCHEMBL14100330 | 0.90 | FLT3 (0.49) | JAK2JAK3JAK1FLT3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | JAK2 1688/4885JAK3 1221/4885JAK1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.